Unlike Johnson & Johnson the previous week, Pfizer Inc.’s* stock price traded up by about 1% in the premarket on its fourth-quarter and full-year 2023 results announcement. This accelerated through its conference call with Pfizer’s stock price initially opening up by about 2% in normal trading. But like J&J, within a few minutes of the market open, Pfizer’s stock headed into the red and closed down by nearly 2% compared with the NYSE Arca Pharmaceutical Index’s (DRG’s) modest loss for the day.
Stock Watch: Vaccines, Oncology Frame Q4 Contrasts Between Pfizer And GSK
The Battle Of The RSV Vaccines Is Only Part Of The Story
While attempting to move beyond post-pandemic unfavorable revenue comparisons, other unfavorable comparisons emerged at Pfizer.
More from Stock Watch
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.